Altimmune, Inc. Common Stock
Symbol: ALT (NASDAQ)
3.71
▲ (0.95%) 0.035
Company Description:
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Key Stats
- Today's Open: $3.67
- Today's High: $3.735
- Today's Low: $3.62
- Today's Volume: 448.75K
- Yesterday Close: $3.67
- Yesterday High: $3.78
- Yesterday Low: $3.6
- Yesterday Volume: 1.67M
- Last Min Volume: 12.74K
- Last Min High: $3.714
- Last Min Low: $3.705
- Last Min VWAP: $3.705
Company Profile
- Name: Altimmune, Inc. Common Stock
- Website: https://www.altimmune.com
- Listed Date: 2005-10-06
- Location: GAITHERSBURG, MD
- Market Status: Active
- CIK Number: 0001326190
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $323.90M
- Round Lot: 100
- Outstanding Shares: 88.26M
- Asset Type: CS
RECENT FILINGS FOR ALT
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-15 | ARS | View |
| 2025-08-15 | DEF 14A | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-08-04 | 4 | View |
| 2025-08-04 | 4 | View |
| 2025-08-04 | 4 | View |
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-06-26 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-13 | 10-Q | View |
| 2025-05-13 | 8-K | View |
| 2025-03-18 | 4 | View |
| 2025-03-14 | 4 | View |
| 2025-03-13 | EFFECT | View |
| 2025-03-13 | 8-K | View |
| 2025-03-11 | 4 | View |
| 2025-03-11 | CORRESP | View |
| 2025-03-05 | UPLOAD | View |
| 2025-02-27 | S-3 | View |
Latest News on ALT